PSI (TFA)

• UNSPSC Description:

  PSI (TFA) is a potent proteasome inhibitor. PSI (TFA) inhibits the proliferation of primary effusion lymphoma (PEL) cells. PSI (TFA) can be used for the research of Kaposi’s sarcoma-associated herpesvirus (KSHV) infection and KSHV-associated lymphomas[1].

• Target Antigen:

  Proteasome

• Type:

  Peptides

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Cancer; Infection

• Assay Protocol:

  https://www.medchemexpress.com/psi-tfa.html

• Solubility:

  10 mM in DMSO

• Smiles:

  OC(C(F)(F)F)=O.O=C([C@H]([C@@H](C)CC)NC(OCC1=CC=CC=C1)=O)N[C@@H](CCC(OC(C)(C)C)=O)C(N[C@@H](C)C(N[C@H](C=O)CC(C)C)=O)=O

• Molecular Weight:

  732.78

• References & Citations:

  [1] Saji C, et al. Proteasome inhibitors induce apoptosis and reduce viral replication in primary effusion lymphoma cells. Biochem Biophys Res Commun. 2011; 415(4):573-8.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported